Delivery Order SPE2DB22D3016-SPE2DB25FBKM4
- Not listed
- The Defense Logistics Agency awarded a $17,009.24 firm fixed-price delivery order to AmerisourceBergen Drug Corp for supply of Tecentriq (atezolizumab) 840 mg/14 mL vials on May 19, 2025, with completion targeted for June 10, 2025. This non-set-aside award represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, which carries a $999,999,999 ceiling and runs through December 2026. The pharmaceutical distributor is...
- The Defense Logistics Agency's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $34,018.40 on September 22, 2025, for the supply of Tecentriq 840 mg/14 ml vials. This is a firm fixed price, non-set-aside contract with an ultimate completion date of October 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Tecentriq is a specialized oncology pharmaceutical product, reflecting the company's role as a...
- The Defense Logistics Agency awarded a $25,189 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Tecentriq Hybridza 1,875 mg 15 ml pharmaceutical product. This is a non-set-aside competitive award with an ultimate completion date of September 30, 2025, and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to the company's corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $8,504.62 on September 19, 2025, for the supply of Tecentriq 840 mg/14 ml vials. This is a firm fixed-price delivery order with an ultimate completion date of October 10, 2025, with performance to be executed at the vendor's facility in Conshohocken, Pennsylvania. The contract represents a non-set-aside award made through open competition, reflecting AmerisourceBergen's demonstrated capability to fulfill...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Tecentriq 840 mg/14 ml vials. The contract is valued at $17,009.24 and operates under a firm fixed price structure with an ultimate completion date of August 11, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through...
- The Defense Logistics Agency awarded a $7,857.72 firm fixed price delivery order to Amerisourcebergen Drug Corporation for the supply of 4561918282 TECENTRIQ 840 MG/14 ML VIAL 14ML pharmaceutical products. Amerisourcebergen Drug Corporation will deliver the products to a location in Conshohocken, Pennsylvania by September 14, 2023 under the terms of the order. The prime contractor, Amerisourcebergen Drug Corporation, is a division of Amerisourcebergen Corporation. No subcontractors or set...
- This federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, is a Delivery Order valued at $21,261.50 under the Defense Logistics Agency (DLA) Troop Support Medical Indefinite Delivery Contract (IDC) valued at $999,999,999. The contract provides for the supply of TECENTRIQ 840 MG/14 ML VIAL 14ML, a pharmaceutical product, to support military treatment facilities, veterans' healthcare programs, and other federal medical...
- On September 19, 2025, the Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for $38,572.76 to supply Actemra 200 mg/10 mL vials. This non-set-aside, competitively awarded contract represents a firm fixed-price delivery order with an ultimate completion date of September 22, 2025. The pharmaceutical product will be delivered to the contractor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of TECENTRIQ HYBREZA 1,875 MG 15ML, a medical product, with a ceiling value of $6,297.24 and a period of performance ending on July 16, 2025. The contract is a firm-fixed-price delivery order, with no set-aside designation, indicating open competition. AmerisourceBergen Drug Corp...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on August 12, 2025, for the supply of Actemra 162 mg/0.9 mL syringes valued at $4,594.53. This firm fixed-price, competitively awarded delivery order is funded by the Defense Logistics Agency's Medical Supply Chain, a defense-focused federal agency, and has an ultimate completion date of August 13, 2025. The award was made under no set-aside designation,...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FBKM4Delivery Order
The Defense Logistics Agency awarded a $8,504.62 delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Tecentriq (atezolizumab) 840 mg/14 ml vials. This is a firm fixed price, non-set-aside contract with an ultimate completion date of October 14, 2025. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999,999,999.00 vehicle running through December 2026 that serves as a comprehensive global pharmaceutical support contract enabling the company to supply pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical federal vendor for medical procurement, particularly for military and veteran healthcare systems. As a prime contractor under the DLA's pharmaceutical supply chain, the company demonstrates extensive capability to fulfill federal medical supply requirements through competitive procurement. The Tecentriq delivery under this award supports the Defense Health Agency and other federal healthcare systems with this specialized oncology medication across multiple therapeutic domains within the military healthcare network.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.5k | 9/22/25 |